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Abstract
Background: Chronic complications of diabetes can be reduced through optimal glycemic and lipid control as
evaluated through measurement of glycosylated hemoglobin (A1C) and low-density lipoprotein cholesterol (LDL-C).
We aimed to produce measures of quality of diabetes care in Saskatchewan and to identify sub-groups at
particular risk of developing complications.
Findings: Prevalent adult cases of diabetes in 2005/06 were identified from administrative databases and linked
with A1C and LDL-C tests measured in centralized laboratories. A1C results were performed in 33,927 of 50,713
(66.9%) diabetes cases identified in Saskatchewan, and LDL-C results were performed in 12,031 of 24,207 (49.7%)
cases identified within the province’s two largest health regions. The target A1C of <= 7.0% and the target LDL-C
of <2.5 mmol/L were achieved in 48.3% and 45.1% of diabetes cases respectively. The proportions were lower
among those who were female, First Nations, non-urban, younger and in lower income quintiles. The same groups
experienced poorer glycemic control (exception females), and poorer lipid control (exception First Nations people).
Among non-Aboriginal people, younger diabetic females were least likely to receive lipid lowering agents.
Conclusions: Linkage of laboratory with administrative data is an effective method of assessing quality of diabetes
care on a population basis and to identify sub-groups requiring particular attention. We found that less than 50%
of Saskatchewan people with diabetes achieved optimal glycemic and lipid control. Disparities were most evident
among First Nations people and young women. The indicators described can be used to provide standardized
information that would support quality improvement initiatives.
Background
Canadians are experiencing an epidemic of diabetes [1,2]
that disproportionately affects First Nations people [3,4].
Although this has serious consequences for individuals,
families and the health care system largely because of
chronic complications, these can be lessened with
improved glycemic and lipid control [5,6].
The Canadian Diabetes Association publishes clinical
practice guidelines that include target values for glycosy-
lated hemoglobin (A1C) and low-density lipoprotein
cholesterol (LDL-C) [7]. We evaluated testing frequency
and outcome measures of A1C and LDL-C indicators to
produce population measures of quality of diabetes care
and to identify sub-groups at particular risk for compli-
cations. This was achieved on a population basis
through linkage of laboratory data with health care
system administrative data.
Methods
Study Populations
This 2005/06 population based study of diabetes care in
Saskatchewan was approved by the University of
Saskatchewan, Saskatoon Health Region and Regina
Qu’Appelle Health Region Ethics Review Boards. Study
populations were identified from Ministry of Health
databases used to administer health care to 99% of the
provincial population [8]. Beneficiaries were sub-divided
into First Nations people (FN) and other Saskatchewan
residents (OSK) by age and sex. FN are indigenous to
Canada and included those registered under Section 6
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but include non-registered FN (<0.5%) and Métis (about
5%) [10]. The provincial population was approximately
one million people and >10% were FN [11].
Diabetic adults aged 20 years and older were identified
using a validated algorithm [12] based on National
Diabetes Surveillance System (NDSS) case definitions
[13]. These required one hospitalization with a discharge
diagnosis of diabetes (ICD-9 250.x or ICD-10-CA E10-
E14.xxx), or two physician service claims for diabetes
within any 730 day period. Gestational diabetes cases
were excluded. We were not able to distinguish between
types 1 and 2 diabetes but <2% of incident diabetes
cases in Canada are <20 years [14], the group with the
highest type 1 diabetes incidence [15].
We define the diabetes incident year as the first fiscal
year (April1 to March 31) in which an individual meets
the diabetes case definition when there has been no
prior diabetes diagnosis for at least two years. There-
after, for each year that an individual is covered by Sas-
katchewan Health, the individual is a prevalent case.
Only prevalent cases of diabetes counted on the first
day (April 1) of the 2005/06 fiscal year were included in
this study; they comprised the core denominators for
our analyses.
Linkage of Diabetes Cases with Laboratory Data
Using encrypted unique identifiers, prevalent cases of
diabetes were linked with laboratory data from centra-
lized laboratories in the two largest Health Regions in
Saskatchewan (Saskatoon and Regina/Qu’Appelle). This
data accounted for nearly 100% of A1C tests and 50% of
LDL-C tests performed in the province.
Quality of Diabetes Care Indicators
Because this study predated the 2008 clinical practice
guidelines [7], we used an A1C target of ≤7.0% for gly-
cemic control and an LDL-C target of <2.5 mmol/L
(now <2.0 mmol/L) for lipid control as published in
2003 [16]. A1C testing was recommended at diabetes
diagnosis and then 3-4 times per year; LDL-C testing
was recommended at diabetes diagnosis and then every
1-3 years as clinically indicated. Finally, we chose an
A1C of >= 9.0% to indicate very poor glycemic control
and a LDL-C of >= 2.5 mmol/L as a level when use of
lipid lowering drugs should be considered.
Based on the above, the quality of care indicators
were: proportion of diabetes cases tested for A1C in
2005/06; of those tested, the proportion with a most
recent A1C <= 7.0%, a most recent A1C >= 9.0% and
the mean of most recent A1C tests; proportion with >=
2 A1C tests/year; proportion with >= 3 A1C tests/year;
proportion of diabetes cases with A1C <= 7.0% by fre-
quency of testing (1, 2, 3, 4+ tests/year); proportion of
diabetes cases ever tested for LDL-C in 2005/06; of
those, the proportion with a latest LDL-C <2.5 mmol/L,
and the mean LDL-C; and proportion of OSK diabetes
cases with an LDL-C >= 2.5 mmol/L dispensed a lipid
lowering drug (not available for FN). Overall results as
well as by sex, ethnicity, location, age group and income
quintile were calculated. Detailed descriptions of indica-
tor derivations can be found in the Saskatchewan Health
Quality Council 2008 Quality Insight report’sT e c h n i c a l
Appendix [17].
Analyses
Most comparisons were made between groups within
specific demographic sub-populations. Mean A1C and
LDL-C values were compared using two tailed t-tests
for two groups and one way Anova for multiple groups.
For between group comparisons, we chose a reference
group and calculated OR’s with 95% confidence intervals
for the remaining groups. Tests for linear trend (one
sided and two sided) were used to compare within
group proportions of diabetes cases with A1C <= 7.0%
by frequency of testing. Data abstraction and analyses
were carried out using SAS software version 9.1.3.
A p value of <= 0.05 was considered significant.
Results
Of the 50,713 prevalent diabetes cases in Saskatchewan
during 2005/06 (Table 1), 24,188 were female (47.7%)
and 6,184 were FN (12.2%). A majority (53.5%) were
urban dwellers and 81% were >= 50 years. Almost half
were in the lowest two income quintiles (48.3%).
Overall, 66.9% of people with diabetes had an A1C
level done during 2005/06. Younger, female, non-urban
people and those with lowest incomes were less likely to
have an A1C test compared to their respective counter-
parts. However, the diabetic groups least likely to have
an A1C test were those under age 40 (53.7%) and FN
(59%). With the exception of females, the same demo-
graphic groups with fewest A1C tests also experienced
the poorest A1C results. FN and those under age 40
exhibited the worst results with mean A1Cs of 8.0% and
8.1% respectively. The group with the best A1C profile
were those aged 70+ (54.3% had A1Cs <= 7%, 7.1% had
A1Cs >= 9% and the mean A1C was 7.2%).
Overall, 38.4% of adults with diabetes had >= 2 and
17.5% had >= 3 A1C tests during 2005/06 (Table 2).
Results were similar between males and females. Non-
urban people were less likely than urban dwellers to
have >1 A1C tests during the year. However, those
tested least frequently were FN.
Overall, the proportion of diabetic people with target
A1Cs decreased from 49.1% of those tested once to
47.3% of those tested >= 4 times (Table 3). This down-
ward trend was mirrored in males and OSK. Only FN
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quency of testing (38.9% of those tested once to 44.9%
of those tested >= 4 times).
Table 4 shows results of LDL-C testing among adults
with diabetes in Saskatchewan’s two most populous
Health Regions. Of the 24,207 prevalent diabetes cases,
11,294 were female (46.7%) and 2,321 were FN (9.6%).
Most were urban (77.3%) and the majority were aged
50+ (80.3%). Almost half (48.7%) were in the lowest two
income quintiles.
Overall, 49.7% of diabetic adults had at least one LDL-
C test during 2005/06. Younger, female, non-urban peo-
ple and those with lowest incomes were less likely to
have an LDL-C test than reference groups. However,
Table 1 Outcomes of A1C testing among Saskatchewan adults with Diabetes by Demographic Characteristics
Characteristic Number of persons with
diabetes†
Tested for A1C Number of persons
tested
A1C <= 7.0% A1C >= 9.0% Mean
A1C
% OR (95%
CI)
% OR (95%
CI)
% OR (95%
CI)
ALL SASK 50713 66.9 33920 48.3 12.6 7.4
female 24188 66.0 0.95(0.92-
0.99)
15971 50.4 1.16(1.11-
1.21)
12.3 0.95(0.89-
1.01)
7.4
1
male* 26525 67.7 17949 46.5 12.9 7.5
ETHNICITY
FN 6184 59.0 0.72(0.68-
0.76)
3646 40.6 0.80(0.74-
0.86)
25.5 2.05(1.88-
2.24)
8.0
1
OSK* 44529 68.0 30274 49.3 11.1 7.4
LOCATION
urban* 27147 68.4 18563 49.9 11.9 7.4
non-urban 23508 65.2 0.86(0.83-
0.89)
15333 46.5 0.86(0.82-
0.90)
13.6 1.23(1.15-
1.31)
7.5
1
AGE (years)
20-29 686 51.2 0.55(0.47-
0.64)
351 40.2 0.56(0.45-
0.69)
24.5 4.26(3.31-
5.49)
8.1
1
30-39 2652 54.3 0.62(0.57-
0.67)
1439 37.0 0.49(0.44-
0.55)
27.4 4.96(4.33-
5.67)
8.1
1
40-49 6287 62.1 0.85(0.80-
0.90)
3902 42.1 0.61(0.57-
0.66)
20.6 3.39(3.06-
3.76)
7.8
1
50-59 10663 69.8 1.20 (1.4-
1.26)
7443 44.4 0.68(0.64-
0.72)
16.6 2.58(2.36-
2.83)
7.6
1
60-69 11596 72.5 1.37(1.30-
1.44)
8408 48.1 0.79(0.74-
0.83)
10.6 1.54(1.40-
1.70)
7.4
1
≥70* 18829 65.7 12377 54.3 7.1 7.2
INCOME
QUINTILE
lowest 12991 63.1 0.76(0.72-
0.81)
8195 46.0 0.81(0.75-
0.86)
15.7 1.53(1.38-
1.69)
7.6
1
second 11496 66.3 0.86(0.82-
0.92)
7626 47.1 0.83(0.78-
0.89)
13.4 1.31(1.18-
1.45)
7.5
1
third 8615 68.8 0.96(0.90-
1.02)
5923 50.3 0.94(0.88-
1.01)
10.9 1.06(0.94-
1.19)
7.3
1
fourth 7589 68.8 0.95(0.89-
1.02)
5220 48.2 0.87(0.81-
0.94)
11.3 1.08(0.96-
1.22)
7.4
1
highest* 9436 69.9 6593 51.2 10.7 7.3
All rates are crude rates
*Reference category
†Includes prevalent diabetes cases aged 20 years and older at beginning of fiscal year 2005/06
Values in this table are based on the last A1C result reported for year
1p<=0 . 0 0 0 1
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people and FN (29.2% versus 51.8% of OSK). Females
displayed among the poorest LDL-C outcomes with only
41.3% achieving target LDL-C levels compared to 48.2%
of males. Mean LDL-C was also poorer for females
(2.8 mmol/L) compared to males (2.6 mmol/L). In con-
trast to A1C findings, FN and non-urban diabetic people
were more likely to achieve target LDL-C levels than
their OSK and urban counterparts.
During 2005/06, 41,934 diabetic OSK lived in Sas-
katchewan for the entire year. Of those, 36.9% were pre-
scribed a lipid lowering agent compared to 38.6% of
20,714 diabetic OSK living in Saskatchewan’st w om o s t
populous Health Regions. Table 5 shows that 6,914 dia-
betic OSK in the two Health Regions had a most recent
LDL-C level >= 2.5 mmol/L, but only 39.2% of those
received a lipid lowering drug. Although no significant
differences were found by location and income quintile,
there was a trend for better treatment rates with
increasing income. The lowest treatment rates were
observed in the oldest and youngest subjects, and
among women. However, both males (27.0%) and
females (18.8%) under age 40 were least likely to receive
treatment.
Discussion
We measured A1C and LDL-C quality of care indicators
in Saskatchewan’s diabetic population by linking health
care system administrative data with laboratory data.
While over 2/3 of people with diabetes received A1C
testing, less than 50% achieved target levels and 12.6%
exhibited very poor glycemic control. Almost 50% of the
study population received LDL-C testing but only 45.1%
of those achieved target levels and only 39.2% of those
Table 2 Frequency of A1C testing among Saskatchewan adults with Diabetes by Demographic Characteristics
Number of persons with diabetes* Persons with >= 2 A1C tests/year Persons with >= 3 A1C tests/year
number % OR (95% CI) number % OR (95% CI)
ALL SASK 48200 18256 38.4 8436 17.5
female 23028 8767 38.1 0.99(0.95-1.03) 4000 17.4 1.00(0.95-1.04)
male† 25172 9759 38.8 4436 17.6
ETHNICITY
FN 5959 1747 29.3 0.69(0.65-0.74) 692 11.6 0.65(0.60-0.71)
OSK† 42241 16779 39.7 7744 18.3
LOCATION
urban† 25809 10351 40.1 4855 18.8
non-urban 22338 8160 36.5 0.85(0.82-0.88) 3572 16.0 0.81(0.77-0.85)
All rates are crude rates
*Includes prevalent diabetes cases aged 20 years and older at beginning of fiscal year 2005/06 and who survived the year with SK Ministry of Health insurance
coverage
†Reference category
Table 3 Outcomes of A1C Testing by Frequency of Testing among Saskatchewan Adults with Diabetes
Persons with
only 1 A1C test/
year
Persons with 2 A1C
tests/year
Persons with 3 A1C
tests/year
Persons with >= 4
A1C tests/year
Test for linear trend
n* % A1C
<= 7.0
n† % A1C <= 7.0 n† % A1C <= 7.0 n† % A1C <= 7.0
ALL SASK 15034 49.1 10336 48.0 5371 47.5 3179 47.3
female 7059 51.3 4864 49.8 2581 49.1 1467 49.7 p = 0.0259 (1 sided) = 0.0517 (2 sided)
Male 7975 47.1 5472 46.4 2790 46.0 1712 45.3 p = 0.0711 (1 sided) = 0.1422 (2 sided)
ETHNICITY
FN 1866 38.9 1073 41.0 453 44.8 254 44.9 p = 0.0035 (1 sided) = 0.0070 (2 sided)
OSK 13168 50.5 9263 48.8 4918 47.7 2925 47.6 p = 0.0001 (1 sided) = 0.0001 (2 sided)
All rates are crude rates
* Denominator is all prevalent diabetes cases aged 20 years and older at the beginning of fiscal year 2005-06
† Includes prevalent diabetes cases defined at beginning of fiscal year 2005/06 and who survived the year with SK Ministry of Health insurance coverage
A1C values in this table are based on the last A1C result reported for year
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scribed a lipid lowering drug.
Diabetic adults who were female, FN, non-urban,
younger or in lower income quintiles were less likely to
receive A1C and LDL-C testing. Apart from females, the
same groups also experienced poorer glycemic control.
While younger subjects and those with lower incomes
also displayed poorer LDL-C results, the largest disparity
was observed between sexes. Females had higher mean
LDL-C concentrations and were less likely to achieve
target LDL-C levels. Despite that, diabetic OSK females
with sub-optimal LDL-C were the group least likely to
receive a lipid lowering agent. This was particularly evi-
dent in younger women, so likely included individuals
with type 1 diabetes. A somewhat unexpected finding
was that FN exhibited better LDL-C profiles than OSK.
Table 4 LDL Cholesterol Indicator outcomes among Diabetic adults in Two Saskatchewan Health regions by
Demographic Characteristics
Number of persons with
diabetes†
Tested for LDL-C Number of persons
tested
LDL-C < 2.5
mmol/L
Mean LDL-C
% OR (95% CI) % OR (95% CI) Mmol/
L
Significance
TOTAL 24207 49.7 12019 45.1 2.7
female 11294 47.6 0.89(0.85-
0.94)
5379 41.3 0.76(0.78-
0.81)
2.8 p < 0.0001
male* 12913 51.4 6640 48.2 2.6
ETHNICITY
FN 2321 29.2 0.38(0.35-
0.42)
677 47.9 1.26(1.07-
1.47)
2.6 p = 0.19
OSK* 21886 51.8 11342 44.9 2.7
LOCATION
urban* 18702 57.1 10679 45.0 2.7
non-urban 5476 24.1 0.23(0.22-
0.25)
1322 46.2 1.03(0.92-
1.15)
2.7 p = 0.18
AGE (years)
20-29 358 29.1 0.49(0.39-
0.62)
104 42.3 0.84(0.57-
1.25)
2.8
30-39 1379 35.1 0.64(0.57-
0.72)
484 39.5 0.75(0.62-
0.91)
2.8
40-49 3040 46.8 1.04(0.96-
1.13)
1423 42.1 0.82(0.73-
0.93)
2.7
50-59 5268 54.5 1.41(1.32-
1.51)
2871 43.4 0.85(0.77-
0.94)
2.7 p = 0.0002
60-69 5428 57.9 1.62(1.51-
1.74)
3144 46.7 0.98(0.89-
1.07)
2.7
≥ 70* 8734 45.7 3993 46.9 2.7
INCOME
QUINTILE
lowest 6170 45.8 0.74(0.69-
0.81)
2826 44.1 0.91(0.81-
1.02)
2.7
second 5630 48.4 0.81(0.74-
0.88)
2726 44.6 0.91(0.81-
1.02)
2.7
third 4499 49.9 0.85(0.78-
0.92)
2247 45.1 0.93(0.82-
1.04)
2.7 p < 0.02
fourth 4044 52.3 0.93(0.85-
1.01)
2116 45.1 0.92(0.81-
1.03)
2.7
highest* 3770 54.8 2067 47.4 2.6
All rates are crude rates
* Reference category
† Includes prevalent diabetes cases aged 20 years and older at beginning of fiscal year 2005/06 in Saskatchewan’s two largest Health Regions
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diabetes care, this observation suggests that there may
be underlying differences in lipid metabolism between
FN and OSK [18].
T h ep r o p o r t i o no fd i a b e t i cp e o p l ea c h i e v i n gt a r g e t
A1C levels decreased with frequency of testing among
OSK but increased among FN. The reasons behind the
former finding are complex but possibly explained in
part by more frequent follow-up care in those with
more brittle or complicated diabetes histories. In con-
trast, the small numbers of FN with more frequent A1C
testing likely represented a subgroup with better dia-
betes care. This suggests that the overall poorer glyce-
mic control experienced by FN may be subject to
improvement through closer monitoring.
Although some of the statistically significant differences
found here (particularly for mean A1C and LDL-C) may
not be clinically problematic, it is important to highlight
that the poorest overall results with respect to frequency
of testing and achievement of target values, occurred
among diabetic FN people and were substantive. While
not unexpected, these findings provide evidence for eth-
nic-based disparities in quality of diabetes care. This is
reflected in higher rates of many diabetes complications
including amputations, strokes and end stage renal disease,
as well as in higher mortality rates among FN as we have
recently shown using the same methodology [19].
Although the reasons behind these disparities are perplex-
ing in the context of a universal health care system, a
recent national survey of diabetes care in FN communities
shows promise in elucidating at least some of the underly-
ing problems by examining individual level factors [20].
Furthermore, these sobering findings and their causes are
highly relevant to other indigenous and developing popu-
lations who are also experiencing disproportionate rates of
diabetes and diabetes complications [21].
Strengths of this study include employment of a vali-
dated algorithm to identify diabetes cases [12], inclusion
of total Saskatchewan populations, ability to carry out a
linkage between laboratory and health care system
administrative data, and the ability to sub-divide the
population by ethnicity. A significant limitation in the
Table 5 Use of Lipid Lowering Drugs among Diabetic OSK With LDL-C >= 2.5 MMOL/L by Demographic Characteristics
Persons with
LDL-C ≥ 2.5 mmol/L†
Persons dispensed a lipid lowering drug Crude rate (%) OR (95% CI)
TOTAL 6914 2711 39.2
AGE (years) Female
20-39 165 31 18.8 0.38 (0.26-0.58)
40-49 389 123 31.6 0.77 (0.60-0.98)
50-59 723 305 42.2 1.21 (1.00-1.46)
60-69 795 329 41.4 1.17 (0.97-1.41)
≥ 70* 1157 435 37.6
AGE (years) Male
20-39 152 41 27.0 0.72 (0.50-1.06)
40-49 428 174 40.7 1.34 (1.07-1.69)
50-59 978 442 45.2 1.61 (1.35-1.93)
60-69 1003 451 45.0 1.60 (1.34-1.91)
≥ 70* 1124 380 33.8
LOCATION
urban* 6196 2416 39.0
non-urban 704 288 40.9 1.09 (0.9-1.3)
INCOME QUINTILE
lowest 1544 569 36.9 0.92 (0.79-1.08)
second 1566 606 38.7 0.97 (0.83-1.13)
third 1320 515 39.0 0.96 (0.82-1.13)
fourth 1267 525 41.4 1.05 (0.90-1.24)
highest* 1191 482 40.5
*Reference category
Drug prescribing data was not available for FN, hence, analysis for lipid lowering prescribing indicators was limited to OSK
Data are stratified by sex because age-sex interaction was present
† Sub-group of prevalent diabetes cases aged 20 years and older at beginning of fiscal year 2005/06 in Saskatchewan’s two largest Health Regions
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unavailability of important individual level health deter-
minants such as smoking, hypertension, and obesity as
well as the inability to determine the impact of accultura-
tion on First Nations people. Other limitations included
an inability to identify people of Aboriginal heritage
other than FN, but this reduces the true differences
between FN and OSK. Second, identifying cases using
administrative data may underestimate the incidence and
prevalence of diabetes [12]. Third, although we could not
differentiate between types 1 and 2 diabetes, most Cana-
dian adults with diabetes have T2DM [14]; the propor-
tion is even higher for FN [15]. Nonetheless, it is likely
that the A1C and LDL-C indicator results for younger
people with diabetes are partly attributable to OSK with
type 1 diabetes. Finally, there may be overlap between the
demographic groups that we have described. In particu-
lar, poorer results for FN in A1C indicators may be partly
related to younger age and lower incomes (or vice versa).
However, that would not explain the poor results among
young OSK (particularly females) regarding treatment
with lipid lowering agents.
Conclusions
Linkage of laboratory data with health care system
administrative data can be used to provide standardized
information for people with diabetes on a population
basis that can be used to identify deficiencies in care
and support quality improvement initiatives. The poten-
tial to do so exists throughout Canada and other juris-
dictions with universal health care systems and/or
electronic medical records serving large patient groups.
For example, a recent study described the utilization
and outcomes of A1C testing among people with dia-
betes in eastern Ontario [22]. Although their results
were consistent with those reported here, they did not
provide information for FN.
We have now shown that less than 50% of diabetes
cases in Saskatchewan achieved optimal glycemic and
lipid control and even smaller proportions were tested
as frequently as recommended. Furthermore, disparities
were most evident among FN who exhibited substan-
tially lower testing rates and poorer glycemic control
than others. The fact that significant gaps exist between
evidence-based guidelines for diabetes care and their
implementation is a cause for concern. These findings
should provide an impetus for understanding those
gaps, and for developing and monitoring new strategies
designed to improve the quality of diabetes care.
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